Mammography demand ebbs
Mammography demand ebbs
A drop in the number of sites offering mammography may be partially to blame for a decline in mammography volume over the last eight years. An IMV Medical Information report on U.S. mammography centers has noted a 16% decline in the number of x-ray breast exams from 43.9 million procedures in 2000 to 36.7 million last year. The number of government-certified mammography centers dropped 16% over this period, from 9910 sites as of May 2000 to 8670 sites as of December 2007. The drop in procedure volume appears to have been steady since 2000, according to the market research firm.
Lawsuit against Emageon evaporates
It was over almost before it started. A shareholder class action lawsuit filed in the Superior Court of Suffolk County, MA, on March 11 alleged, among other things, that the Emageon board of directors violated its fiduciary duties by not maximizing value for the company's shareholders when entering into the planned merger Feb. 23 with Amicas. But the suit didn't last long. The plaintiff withdrew the complaint five days later, according to an 8-K filing with the Securities and Exchange Commission.
TeraRecon reaches milestone
More than 10,000 licenses have been issued worldwide by TeraRecon for the use of its Aquarius advanced visualization technology. The milestone gives provides bragging rights for the greatest market share in the direct-to-end-user market for advanced visualization, according to the company.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
